|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,173.80 INR | +1.37% |
|
+0.35% | +6.81% |
| 06-11 | Glenmark Pharmaceuticals Unit Launches Acne Treatment Winlevi in European Markets | MT |
| 06-11 | Cosmo Pharmaceuticals Flags Launch of Acne Treatment in Key Markets Across Europe | MT |
| Market Cap | 613B 6.45B 5.57B 5.14B 4.81B 9.03B 9.16B 60.87B 23.68B 298B 24.21B 23.69B 1,034B | P/E Ratio 2026 |
44.2x | P/E Ratio 2027 * | 26.3x |
|---|---|---|---|---|---|
| Enterprise Value | 574B 6.04B 5.22B 4.81B 4.5B 8.45B 8.57B 56.97B 22.17B 279B 22.66B 22.17B 968B | EV / Sales 2026 |
3.51x | EV / Sales 2027 * | 3.45x |
| Free-Float |
51.03% | Yield 2026 |
0.12% | Yield 2027 * | 0.27% |
Last Transcript: Glenmark Pharmaceuticals Limited
| 1 day | +1.37% | ||
| 1 week | +0.35% | ||
| Current month | -4.44% | ||
| 1 month | -3.69% | ||
| 3 months | -3.66% | ||
| 6 months | +10.07% | ||
| Current year | +6.81% |
| 1 week | 2,117 |  | 2,252.5 |
| 1 month | 2,117 | | 2,427 |
| Current year | 1,842 | | 2,474 |
| 1 year | 1,625 | | 2,474 |
| 3 years | 621.8 | | 2,474 |
| 5 years | 348.5 | | 2,474 |
| 10 years | 161.65 | | 2,474 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 1999-12-31 | |
Anurag Mantri
DFI | Director of Finance/CFO | 54 | 2025-05-26 |
Indrajit Bose
PSD | President | - | 2023-09-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Cherylann Pinto
BRD | Director/Board Member | 58 | - |
| Chairman | 56 | 2011-05-11 | |
| Director/Board Member | 85 | 2009-08-13 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.37% | +0.35% | +32.58% | +240.43% | 6.45B | |
| +0.75% | +1.43% | +7.13% | +83.44% | 45.63B | |
| -0.20% | -3.59% | +38.01% | +87.26% | 33.53B | |
| +0.44% | -0.85% | -7.55% | +44.74% | 11.81B | |
| -0.11% | +1.44% | +12.86% | +116.61% | 11.69B | |
| +0.59% | +0.78% | +36.70% | +126.43% | 9.12B | |
| +2.40% | +0.08% | +17.77% | +43.22% | 7.16B | |
| -1.12% | -0.56% | +40.12% | -18.60% | 6.49B | |
| +0.51% | -3.04% | -42.24% | -5.52% | 5.16B | |
| -0.39% | +5.19% | +14.68% | +117.63% | 4.11B | |
| Average | +0.42% | +0.45% | +15.01% | +83.56% | 14.12B | |
| Weighted average by Cap. | +0.40% | -0.14% | +17.26% | +84.83% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 153B 1.61B 1.39B 1.28B 1.2B 2.25B 2.29B 15.19B 5.91B 74.47B 6.04B 5.91B 258B | 167B 1.75B 1.52B 1.4B 1.31B 2.45B 2.49B 16.55B 6.44B 81.14B 6.58B 6.44B 281B |
| Net income | 20.53B 216M 187M 172M 161M 302M 307M 2.04B 793M 9.99B 810M 793M 34.6B | 23.11B 243M 210M 194M 181M 340M 345M 2.29B 892M 11.24B 912M 893M 38.95B |
| Net Debt | -39.29B -413M -357M -329M -308M -578M -587M -3.9B -1.52B -19.11B -1.55B -1.52B -66.22B | -37.1B -390M -337M -311M -291M -546M -554M -3.68B -1.43B -18.05B -1.46B -1.43B -62.52B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-12 | 2,173.80 ₹ | +1.37% | 500,898 |
| 26-06-11 | 2,144.50 ₹ | +0.00% | 353,598 |
| 26-06-10 | 2,144.40 ₹ | -2.95% | 1,127,230 |
| 26-06-09 | 2,209.60 ₹ | +1.52% | 561,403 |
| 26-06-08 | 2,176.50 ₹ | +0.48% | 491,134 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GLENMARK Stock
Select your edition
All financial news and data tailored to specific country editions
